Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology
Disease Category: Acute Myelogenous Leukemia (AML)
Trial Information
Trial of CPX-351 in Newly Diagnosed Edlerly AML Patients
The study investigates if CPX-351 will be a) more effective than the standard AML treatment and b) more tolerable than the standard AML treatment regimens. The study compares the investigational product CPX-351 vs the standard treatment for AML in this patients age group.
Patient Inclusion Criteria:
- Age =60 and <76 years at the time of diagnosis of AML
- Pathological confirmation of AML
- Cardiac ejection fraction > 50% by echocardiography or MUGA scan
Patient Exclusion Criteria:
- Prior treatment for AML; only hydroxyurea is permitted
- Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16 if known at the time of randomization
- Patients with a prior anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent)
Cathy Spears, Research Manager
St. Francis Hospital and Health Centers
1500 N Albany Street, Suite 1001
Beech Grove, IN 46107
Phone: 317-782-7819
Fax: 317-782-7828
EMail: cathy.spears@ssfhs.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
